课题基金 / 基金详情

Circulating Osteoblast Lineage Cells in Hypoparathyroidism

Circulating Osteoblast Lineage Cells in Hypoparathyroidism
甲状旁腺功能减退症中的循环成骨细胞谱系细胞
批准号:
7362389
负责人:
MISHAELA R RUBIN
金额:
$7.89万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-04-01 至 2009-03-31

项目摘要

项目成果

MISHAELA R RUBIN的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供): 甲状旁腺功能减退症是一种罕见的疾病,血液循环中缺少甲状旁腺激素(PTH)。如果没有甲状旁腺激素,骨骼就不会经历正常的骨转换,这是健康的骨骼重塑所必需的过程。我的K23的重点是测试甲状旁腺激素对正常骨骼结构和功能必不可少的假设。我正在研究30名甲状旁腺功能减退症患者在甲状旁腺激素置换前后的骨质量。我的第一个目标是彻底描述甲状旁腺功能低下状态下的骨骼特征。到目前为止,我对19名甲状旁腺功能减退症患者进行了经皮髂骨活组织检查,朝着这个最初的目标取得了重大进展。初步数据显示,甲状旁腺功能减退症患者的骨转换受到严重抑制,骨质量指标明显异常。K23的第二个目标是对甲状旁腺功能减退症患者进行甲状旁腺激素治疗,并测试甲状旁腺激素缺乏状态下的骨骼异常特性如何归因于甲状旁腺激素缺乏。我目前正在对19名研究对象实施甲状旁腺素(1-84)。初步数据表明,甲状旁腺素置换正在恢复正常的骨转换。随着项目的进行,追求项目目标的其他方面,我预计随之而来的骨骼质量的改善将是显而易见的。最初的应用中有一个领域没有被提议用于研究,这与甲状旁腺素调节骨转换和改善骨质量的潜在机制有关。一个吸引人的机制是,甲状旁腺素提供了新的成骨细胞,这些细胞可用于增强骨重建。最近,人们观察到在外周血中可以检测到大量的成骨细胞系细胞。为了扩大K23的研究目标,我将测试甲状旁腺激素用于甲状旁腺功能减退症受试者时增加循环成骨细胞系细胞数量的假设。因此,除了继续追求K23奖的最初目标外,我还将进行一项先导性研究,以确定甲状旁腺功能减退症是否与循环中的成骨细胞系细胞减少有关,以及甲状旁腺素替代疗法是否提供更多的这些细胞。我期望在这一新的研究途径中获得的数据将导致进一步的研究,以更机械地描绘PTH如何影响成骨细胞的谱系特性,不仅在甲状旁腺功能减退症中,而且在原发性甲状旁腺功能亢进症和甲状旁腺功能亢进症治疗骨质疏松后。这个项目将继续和扩大我正在进行的甲状旁腺激素改善骨骼质量的行动的研究。计划进行更多的研究,以获得关于一种吸引人的机制的新信息,以解释这些观察结果,即增加成骨细胞或骨构建细胞的可用性。
英文摘要
DESCRIPTION (provided by applicant): Hypoparathyroidism is an uncommon disorder in which parathyroid hormone (PTH) is absent from the circulation. Without PTH, the skeleton does not undergo normal bone turnover, a process that is essential for healthy skeletal remodeling. The focus of my K23 is to test the hypothesis that PTH is essential for normal skeletal structure and function. I am studying bone quality in 30 patients with hypoparathyroidism before and after PTH replacement. My first goal is to characterize thoroughly the skeleton in the hypoparathyroid state. I have made significant progress toward this original goal by performing percutaneous iliac crest bone biopsies on 19 subjects to date with hypoparathyroidism. The preliminary data indicate that bone turnover in hypoparathyroidism is profoundly suppressed and that indices of bone quality are markedly abnormal. The second goal of the K23 is to administer PTH to subjects with hypoparathyroidism and to test how the abnormal properties of bone that were characterized in the PTH-deficient state could be attributed to the lack of PTH. I am currently administering PTH(1-84) to 19 study subjects. The preliminary data suggest that PTH replacement is restoring bone turnover to normal. As the project proceeds, pursuing other aspects of the goals of the project, I expect that concomitant improvements in bone quality will be demonstrable. One area of the original application that was not proposed for study relates to underlying mechanisms that can account for PTH's actions to regulate bone turnover and improve bone quality. One attractive mechanism is that PTH is providing new osteoblasts that become available for enhanced bone remodeling. Recently, it has been observed that osteoblast lineage cells can be detected in significant numbers in the peripheral blood. To expand the research objectives of the K23, I will test the hypothesis that PTH increases the number of circulating osteoblast lineage cells when administered to subjects with hypoparathyroidism. Thus, in addition to continuing to pursue the original goals of the K23 award, I will conduct a pilot study to determine whether hypoparathyroidism is associated with reduced circulating osteoblast lineage cells and whether PTH replacement provides a greater supply of these cells. I expect that the data acquired in this new avenue of research will lead to further studies to delineate more mechanistically how PTH affects osteoblast lineage properties, not only in hypoparathyroidism, but also in primary hyperparathyroidism and after PTH treatment for osteoporosis. This project will continue and extend my ongoing investigation into the actions of parathyroid hormone to improve bone quality. Additional studies are planned to gain new information about an attractive mechanism to account for these observations, namely an effect to increase the availability of osteoblast, or bone-building, cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Continuous calcium sensor patch for hypoparathyroid patients
Continuous calcium sensor patch for hypoparathyroid patients
Skeletal Fragility in Type 1 Diabetes: Glycemic Control and Bone Strength
Skeletal Health in Youth with Type 1 Diabetes and Gender Diversity
海外基金